TY - JOUR
T1 - Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"
AU - Lazaridis, Konstantinos N.
AU - Gores, Gregory J.
AU - Lindor, Keith D.
PY - 2001
Y1 - 2001
N2 - UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.
AB - UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.
UR - http://www.scopus.com/inward/record.url?scp=0034945397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034945397&partnerID=8YFLogxK
U2 - 10.1016/S0168-8278(01)00092-7
DO - 10.1016/S0168-8278(01)00092-7
M3 - Review article
C2 - 11495032
AN - SCOPUS:0034945397
SN - 0168-8278
VL - 35
SP - 134
EP - 146
JO - Journal of hepatology
JF - Journal of hepatology
IS - 1
ER -